Abstract
Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.
Keywords
MedicineClinical trialCarcinogenDrugPharmacologyCancerBioinformaticsInternal medicine
Affiliated Institutions
Related Publications
Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion
Dioxin and certain structurally related compounds increase the incidence of liver neoplasms in rodents upon chronic bioassay. Short-term studies indicate the lack of direct DNA-...
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
BACKGROUND HMG CoA reductase inhibitors (or statins), a new class of lipid-lowering compounds, have raised expectations for more widespread use than that of the older lipid-lowe...
Tumor angiogenesis: past, present and the near future
The concept of treating solid tumors by inhibiting tumor angiogenesis was first articulated almost 30 years ago. For the next 10 years it attracted little scientific interest. T...
Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome
Immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX, OMIM 304790) is a rare, recessive disorder resulting in aggressive autoimmunity and early death. Mutations ...
Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
The Coronary Drug Project was conducted between 1966 and 1975 to assess the long-term efficacy and safety of five lipid-influencing drugs in 8,341 men aged 30 to 64 years with e...
Publication Info
- Year
- 1996
- Type
- letter
- Volume
- 275
- Issue
- 1
- Pages
- 55-55
- Citations
- 372
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
372
OpenAlex
Cite This
Thomas B. Newman
(1996).
Carcinogenicity of Lipid-Lowering Drugs.
JAMA
, 275
(1)
, 55-55.
https://doi.org/10.1001/jama.1996.03530250059028
Identifiers
- DOI
- 10.1001/jama.1996.03530250059028